Palovarotene clinical trials
How each study uses Palovarotene is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 16 Aug 2023 · SOHONOS · NDA 215559 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Palovarotene
- 7
Studies by the year they started
8 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses Palovarotene is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single DoseCompletedPhase 1IpsenNCT06908954Written as Palovarotene
- A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.CompletedPhase 3IpsenNCT05027802Written as Palovarotene
- An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.CompletedPhase 3Clementia Pharmaceuticals Inc.NCT03312634Written as Palovarotene
- An Efficacy and Safety Study of Palovarotene for the Treatment of MOTerminatedPhase 2Clementia Pharmaceuticals Inc.NCT03442985Written as Palovarotene 2.5 mg
- Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult SubjectsCompletedPhase 1Clementia Pharmaceuticals Inc.NCT04829773Written as Palovarotene
- Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult SubjectsCompletedPhase 1Clementia Pharmaceuticals Inc.NCT04762355Written as Palovarotene
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP SubjectsCompletedPhase 2Clementia Pharmaceuticals Inc.NCT02190747Written as Palovarotene
- In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) SubjectsTerminatedPhase 2Clementia Pharmaceuticals Inc.NCT02521792Written as Palovarotene
Codes
What other systems call Palovarotene · ClinicalTrials.gg INT005560
- MeSH (NLM) C546535PalovaroteneOne source NLM
- UNII (FDA) 28K6I5M16GPALOVAROTENEConfirmed FDA, NLM, Wikidata
- Wikidata Q15708269palovaroteneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80661PalovaroteneOne source FDA
- DrugBank DB05467One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546535 | Palovarotene | One source NLM |
| UNII (FDA) | 28K6I5M16G | PALOVAROTENE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15708269 | palovarotene | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80661 | Palovarotene | One source FDA |
| DrugBank | DB05467 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.